Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.84

+1.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (9204)	9/25/2003 2:24:40 PM
From: Icebrg	Read Replies (1) of 52153

>>>>But fundamental news was good>>>> Alertness Drug Backed for Some New Uses Thursday September 25, 2:04 pm ET BETHESDA, Md. (Reuters) - A U.S. advisory panel on Thursday backed Cephalon Inc.'s (NasdaqNM:CEPH - News) drug Provigil to combat excessive sleepiness due to shift work or severe snoring that causes individuals to wake frequently. But the Food and Drug Administration (News - Websites) advisers split 4-4 on whether Cephalon should be allowed to market Provigil more broadly for excessive sleepiness from other sleep disorders. The FDA usually follows the advice of its advisory panels. Provigil already is approved for treating narcolepsy, a rare condition that causes uncontrollable sleeping during waking hours. It seems (to me) that they will get what they want. Perhaps not the very broad label incorporating everything, but enough to make it worthwhile (and legal) to start visiting general practitioners. The idea is of course that once these MDs are getting more comfortable prescribing the drug they will start doing it off-label. In exactly the same way that they managed to expand from the narcolepsy base. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next